Shamburg News · 8-K filed Nov 4, 2026, 7:34 AM EST

Medline Reports Third Quarter 2026 Results, Raises Organic Sales Guidance, Authorizes $1 Billion Buyback

MDLN · Medline Inc.

  • Earnings
  • Financing
  • Materiality: high

Medline Inc. reported third quarter 2026 net sales of $7.9 billion, up 10.4%, and net income of $318 million, down 1.2%, with Adjusted EBITDA of $960 million, up 11.8%. Diluted EPS was $0.22 for the quarter and $0.45 for the nine months, with Adjusted Diluted EPS of $0.44 and $1.27. The company raised its full year 2026 Organic Sales growth outlook to 10.0% to 10.5% and reaffirmed Adjusted EBITDA guidance of $3.3 billion to $3.4 billion. The Board approved a share repurchase program of up to $1 billion.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0002046386-26-000060.

Written from the filing by Shamburg Markets. Figures are as reported by the company.